150 related articles for article (PubMed ID: 22873829)
1. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.
Fianchi L; Criscuolo M; Breccia M; Maurillo L; Salvi F; Musto P; Mansueto G; Gaidano G; Finelli C; Aloe-Spiriti A; Santini V; Greco M; Hohaus S; Leone G; Voso MT
Leuk Lymphoma; 2013 Mar; 54(3):658-61. PubMed ID: 22873829
[No Abstract] [Full Text] [Related]
2. Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
Niscola P; Tendas A; Abruzzese E; Caravita T; Cupelli L; Giovannini M; Scaramucci L; Siniscalchi A; Trawinska MM; de Fabritiis P
Ann Hematol; 2017 Sep; 96(9):1591-1593. PubMed ID: 28702776
[No Abstract] [Full Text] [Related]
3. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.
Thorpe M; Montalvão A; Pierdomenico F; Moita F; Almeida A
Leuk Res; 2012 Aug; 36(8):1071-3. PubMed ID: 22607959
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
Niscola P; Siniscalchi A; Tendas A; Scaramucci L; Fratoni S; de Fabritiis P; Caravita T
Ann Hematol; 2015 Oct; 94(10):1753-4. PubMed ID: 26088814
[No Abstract] [Full Text] [Related]
5. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
[No Abstract] [Full Text] [Related]
6. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
7. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.
Drummond MW; Pocock C; Boissinot M; Mills J; Brown J; Cauchy P; Cross NC; Hartley S; Kell J; Szubert A; Cockerill PN; Bowen DT
Leukemia; 2014 Jul; 28(7):1570-2. PubMed ID: 24569776
[No Abstract] [Full Text] [Related]
8. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.
Serrao A; Loglisci G; Salaroli A; Zacheo I; Alimena G; Breccia M
Leuk Lymphoma; 2013 Feb; 54(2):411-2. PubMed ID: 22694794
[No Abstract] [Full Text] [Related]
10. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?
Breccia M; Voso MT; Alimena G
Leuk Res; 2013 Feb; 37(2):204-5. PubMed ID: 23174191
[No Abstract] [Full Text] [Related]
11. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
Iastrebner M; Jang JH; Nucifora E; Kim K; Sackmann F; Kim DH; Orlando S; Jung CW; Basquiera A; Klein G; Santini F; Bernard HI; Korin J; Taborda G
Leuk Lymphoma; 2010 Dec; 51(12):2250-7. PubMed ID: 20929328
[TBL] [Abstract][Full Text] [Related]
12. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
13. Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
Hilmi M; Bally C; Burns R; Lorillon G; Bergeron A; Fenaux P; Ades L
Ann Hematol; 2018 Mar; 97(3):541-542. PubMed ID: 29170809
[No Abstract] [Full Text] [Related]
14. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
Wang L; Wang HX; Zhao J
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):497. PubMed ID: 22213878
[No Abstract] [Full Text] [Related]
17. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment.
Di Battista V; Matteucci C; Pulini S; Calabrese G; Quintini M; Moretti M; Ballanti S; Canino S; Di Bartolomeo P; Mecucci C
Eur J Dermatol; 2017 Oct; 27(5):540-542. PubMed ID: 29084640
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
20. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
Shah D; Kumar R; Gaikazian S
Haemophilia; 2014 Jan; 20(1):e92-4. PubMed ID: 24261579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
